Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Respiratory Medicine|September 19, 2017
Long-term safety of glycopyrrolate/eFlow<sup>®</sup> CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized studyGary T Ferguson, Thomas Goodin, Robert Tosiello, et al.
Current Opinion in Pulmonary Medicine|October 10, 2017
Chronic obstructive pulmonary disease in the long-term care setting: current practices, challenges, and unmet needsManuel Suarez-Barcelo, Joseph L Micca, Sharon Clackum, et al.
Chest|June 11, 2003
Cardiovascular safety of salmeterol in COPDGary T Ferguson, Christian Funck-Brentano, Tracy Fischer, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 29, 2021
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium TherapyGary T Ferguson, Edward M Kerwin, Tara Rheault, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 22, 2020
The Effect of Metabolic Syndrome Status on Lung Function and Patient-reported Outcomes in Patients with COPD Receiving Nebulized GlycopyrrolateBrian Carlin, Gary T Ferguson, Ayca Ozol-Godfrey, et al.
Respiratory Research|July 31, 2019
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized studyEdward M Kerwin, Gary T Ferguson, Mindy Mo, et al.
Thorax|March 19, 2013
Number needed to treat in COPD: exacerbations versus pneumoniasOliver N Keene, Antonio Anzueto, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 19, 2025
Albuterol Digihaler in COPD Disease Management: A Real-World Study to Assess Digihaler Inhalation Parameters, Thresholds and Their Use to Identify Deterioration in Clinical PracticeGary T Ferguson, Amanda Boe, Tanisha D Hill, et al.
American Journal of Respiratory and Critical Care Medicine|August 14, 2020
Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally ImportantDonald A Mahler, Jill A Ohar, Gary T Ferguson, et al.
Advances in Therapy|July 17, 2020
Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical TrialsRoland Buhl, Alberto de la Hoz, Wenqiong Xue, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Respiratory Medicine|September 19, 2017
Long-term safety of glycopyrrolate/eFlow<sup>®</sup> CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized studyGary T Ferguson, Thomas Goodin, Robert Tosiello, et al.
Current Opinion in Pulmonary Medicine|October 10, 2017
Chronic obstructive pulmonary disease in the long-term care setting: current practices, challenges, and unmet needsManuel Suarez-Barcelo, Joseph L Micca, Sharon Clackum, et al.
Chest|June 11, 2003
Cardiovascular safety of salmeterol in COPDGary T Ferguson, Christian Funck-Brentano, Tracy Fischer, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 29, 2021
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium TherapyGary T Ferguson, Edward M Kerwin, Tara Rheault, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 22, 2020
The Effect of Metabolic Syndrome Status on Lung Function and Patient-reported Outcomes in Patients with COPD Receiving Nebulized GlycopyrrolateBrian Carlin, Gary T Ferguson, Ayca Ozol-Godfrey, et al.
Respiratory Research|July 31, 2019
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized studyEdward M Kerwin, Gary T Ferguson, Mindy Mo, et al.
Thorax|March 19, 2013
Number needed to treat in COPD: exacerbations versus pneumoniasOliver N Keene, Antonio Anzueto, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 19, 2025
Albuterol Digihaler in COPD Disease Management: A Real-World Study to Assess Digihaler Inhalation Parameters, Thresholds and Their Use to Identify Deterioration in Clinical PracticeGary T Ferguson, Amanda Boe, Tanisha D Hill, et al.
American Journal of Respiratory and Critical Care Medicine|August 14, 2020
Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally ImportantDonald A Mahler, Jill A Ohar, Gary T Ferguson, et al.
Advances in Therapy|July 17, 2020
Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical TrialsRoland Buhl, Alberto de la Hoz, Wenqiong Xue, et al.
Pageof 11